R&D

实验室8

To fully utilize the flexibility of the DiKineTM  and the long-acting multi-specific antibodies platform, Evive is actively exploring next generation products that target multiple targets or pathways during disease development and progression. Cytokines, hormones, and their agonists/antagonists are among the primary targets for the DiKineTM  platform products. Disruption of multiple pathways during cancer development are slated for the long-acting multi-specific antibodies platform products.